Mustang Bio

Mustang Bio is a clinical-stage biopharmaceutical company dedicated to translating breakthroughs in cell therapy into potential cures for cancers with high unmet medical need. Its strategy centers on a capital-efficient model of in-licensing first-in-class candidates, primarily CAR T therapies, from top-tier research institutions like City of Hope. The company has advanced a pipeline of CAR T programs into clinical trials for aggressive brain tumors and hematologic malignancies, with recent Phase 1 data showing promising survival signals. A key pillar of its approach is developing advanced, controlled manufacturing processes to overcome the scalability challenges inherent in cell therapy.

An operational platform focused on the strategic in-licensing of first-in-class cell therapy candidates from leading research institutions, coupled with expertise in clinical development and advanced, scalable manufacturing process development.

In glioblastoma, Mustang competes against a barren standard-of-care landscape but faces other investigational therapies; success requires demonstrating a clear survival advantage. In hematologic cancers, it confronts dominant, approved CD19 CAR-T products from major pharma, necessitating differentiation through its CD20 target and efficacy in niche subtypes like Waldenström macroglobulinemia.